Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
426 Leser
Artikel bewerten:
(2)

Bioz, Inc.: EpiCypher Partners With Bioz to Facilitate High-Quality Research by Displaying Scientific Product Citations

PALO ALTO, CA / ACCESSWIRE / February 28, 2024 / Bioz, Inc., a leading AI software company committed to advancing scientific discovery, is pleased to spotlight its strategic partnership with EpiCypher, a prominent player in the realm of epigenetics and chromatin science.

Bioz Content Hub

Bioz Content Hub
Bioz Content Hub on EpiCypher's Website

Through this new strategic partnership, Bioz has incorporated its dynamic digital widgets, called Bioz Badges and Content Hubs, onto EpiCypher's website (both onto product pages and onto a standalone page). These widgets feed real-time citation data to the website in order to support researchers in their decision-making process. The data displayed includes snippets from peer-reviewed publications, live citation counts, and objective Bioz Stars ratings that showcase successful product usage in prior research. EpiCypher's Badges and Content Hub drive product validation for EpiCypher's customers, allowing for more effective research.

Dr. Karin Lachmi, Co-Founder and CRO of Bioz, expresses enthusiasm for this partnership by stating, "We celebrate a successful partnership with EpiCypher and are proud to align with a company committed to scientific excellence." Dr. Lachmi added that "Bioz Badges are guiding EpiCypher's customers towards the most effective products for their research experiments."

Keith Maier, Associate Director of Product Development at EpiCypher said that "we are seeing increased user engagement, by displaying to our research-focused customer base how our products have contributed to peer-reviewed research. This enhancement not only helps new customers source our products with confidence but also serves as a valuable internal resource."

Renowned for its innovative products in Epigenetics research, EpiCypher offers a range of products such as reagents, assays, kits, and assay services. Their contributions are backed by >1,500 peer-reviewed publications, visible through their Bioz Badges and Content Hub. These integrations efficiently showcase product usage in peer-reviewed literature, highlighting more than 300 publications in the past year alone that used EpiCypher's breakthrough CUTANATM CUT&RUN/CUT&Tag genomic mapping technologies. This collaboration is positioned to fortify researchers with unprecedented confidence while furthering the companies' joint commitment to advancing scientific discovery.

About Bioz
Bioz is the world's most advanced AI search engine for scientific experimentation, with evidence-based ratings and recommendations to guide scientists toward the most validated products for their experiments, accelerating research toward new discoveries. Bioz solutions for suppliers include Bioz Badges and Content Hubs, web-based widgets, that are placed on product supplier websites to increase user engagement and sales conversion.

About EpiCypher
EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. EpiCypher is at the forefront of chromatin mapping technologies with the CUTANA platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services.

Helpful Links

  • Bioz
  • Bioz Badges
  • Bioz Stars
  • EpiCypher

To learn more about Bioz solutions for suppliers, please reach out to info@bioz.com.

To learn more about EpiCypher products and services, please reach out to info@epicypher.com. EpiCypher® and CUTANA® are registered trademarks of EpiCypher, Inc.

Contact Information
Daniel Levitt
CEO
pr@bioz.com

Keith Maier
Associate Director of Product Development
kmaier@epicypher.com

SOURCE: Bioz, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.